Physician profile
Hashem Younes
NPI 1184864845
$434,748.56
in general payments reported to CMS, 2019-2025
23 companies · $53K in 2025
The $53K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $20K · 2021: $25K · 2022: $98K · 2023: $96K · 2024: $88K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $195K · Travel and Lodging: $31K · Consulting Fee: $6,015 · Food and Beverage: $4,632 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $195,074.50 |
| Travel and Lodging | $30,503.47 |
| Consulting Fee | $6,015.00 |
| Food and Beverage | $4,632.26 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $207,883.99 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $122,395.98 | 2019-2025 | Keytruda |
| Pfizer INC. | $67,639.39 | 2020-2024 | |
| Array Biopharma INC | $15,930.84 | 2019-2025 | Braftovi, Mektovi |
| Genentech USA, INC. | $15,718.74 | 2019 | |
| Seagen INC. | $2,242.50 | 2020 | |
| Novartis Pharmaceuticals Corporation | $1,312.50 | 2022 | |
| Celgene Corporation | $957.15 | 2019-2024 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $162.99 | 2019-2020 | |
| Lilly USA, LLC | $128.25 | 2019 | |
| Iovance Biotherapeutics, INC. | $120.99 | 2024 | Amtagvi |
| Incyte Corporation | $65.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $34.61 | 2025 | Libtayo |
| Tempus Ai, INC | $26.05 | 2024 | Xt Cdx |
| Genmab U.S., INC. | $22.34 | 2025 | Epkinly |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Amgen INC. | $19.85 | 2023 | Blincyto, Kyprolis |
| Myriad Genetic Laboratories, INC. | $18.96 | 2025 | Precisetumor |
| Beigene USA, INC. | $17.95 | 2021 | |
| Glaxosmithkline, LLC. | $16.09 | 2024 | Jemperli, Zejula |
| Astellas Pharma US INC | $13.39 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hashem Younes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.